« Return to News | CROs/Service Providers

Etrials Restructuring—Again

Monday, December 22, 2008 11:13 AM

A month after naming a new permanent CEO, beleaguered eClinical company etrials is reorganizing its management structure—a move that will result in the departure of once-interim CEO Chuck Piccirillo as well as two other senior executives.

This is the second major management restructuring for etrials in 2008. Earlier this year, the company lost its CEO, chief financial officer, and chief operating officer (whose position was eliminated).

Piccirillo served as CEO from July to November while the company launched an executive search to replace Chip Jennings, who resigned suddenly in July. Piccirillo was replaced by permanent CEO M. Denis Connaghan in November and resumed his position as vice president of technology.

The reorganization, according to a company statement, is intended to better align operations with customer need and more effectively leverage strengths. However, the announcement comes after more than a year of financial struggle for the Morrisville, N.C.-based company.

In November, etrials reported a $6.1-million net loss for the third quarter. The company’s share prices have dropped almost 70% since the start of the year to $0.84 in morning trading.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.